Value-based medicine's comparative effectiveness and cost-effectiveness analyses: 27,000,000 possible input variants

Evidence-Based Ophthalmology

Volumn 12, Issue 1, 2011, Pages 52-57

  Brown, Gary C ^a   Brown, Melissa M ^a   Kertes, Peter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; EVIDENCE BASED MEDICINE; HEALTH ECONOMICS; MEDICINE; METHODOLOGY; PATIENT PREFERENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUESTIONNAIRE; UNITED STATES; VALUE BASED MEDICINE; VISION;

EID: 78651348544     PISSN: 15559203     EISSN: 15559211     Source Type: Journal    
DOI: 10.1097/IEB.0b013e3182049394     Document Type: Article

References (30)

1. Congress of the United States Congressional Budget Office. A CBO paper. Research on the comparative effectiveness of medical treat-ments. From the Internet @ http://www.cbo.gov/ftpdocs/88xx/doc8891/12-18-Comparative Effectiveness.pdf (Accessed May 7, 2009).
2. Brown MM, Brown GC Comparative effective-ness and translational medicine. Evidence-Based Ophthalmol. 2008;9:11-13.
3. Brown MM, Brown GC, Brown HC, et al. The comparative effectiveness and cost-effective-ness of vitreoretinal interventions. Curr Opin Ophthalmol. 2008;19:202-207.
4. American Recovery and Reinvestment Act of 2009. NIH Challenge Grants in Health and Science Research (RFA-OD-09-003). From the Internet @ http://grants.nih.gov/grants/funding/challenge-award/. (Accessed April 22, 2009).
5. Brown MM, Brown GC, Sharma S. Evidence-Based Medicine to Value-Based Medicine. Chicago: AMA Press; 2005:1-324.
6. Ware JE Jr, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36). Medical Care. 1992;30:473-483.
7. National Eye Institute. National Eye Institute Visual Functioning Questionnaire-25 http://www. nei. nih.go v/reso urces/visio nfunction/vfq- ia.pdf (Accessed June 26, 2009).
8. Brown MM, Brown GC, Sharma S, et al. Health care economic analyses and value-based medi-cine. Surv Ophthalmol. 2003;48:204-223
9. Branch Retinal Vein Occlusion Study Group. Argon laser for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98: 271-282.
10. Klarman H, Francis J, Rosenthal G. Cost-effec-tiveness applied to the treatment of chronic renal disease. Medical Care. 1968;6:48-55.
11. Weinstein MC, Stasson WB. Foundations of cost-effectiveness analysis for health and med-ical practices. N Eng J Med. 1977;296:716-721.
12. Gold ME, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
13. Brown MM, Brown GC, Sharma S, et al. Evidence-based medicine, utilities and quality of life. CurrOpin Ophthalmol. 1999;10:221-228.
14. Angell M. Patients' preferences in randomized clinical trials. N Engl J Med. 1984;310:1385-1387
15. Kassirer JP. Incorporating patients' preferences into medical decisions. N Engl J Med. 1994;330: 1895-1896.
16. Brown GC, Brown MM, Sharma S. Difference between ophthalmologist and patient percep-tions of quality-of-life associated with age-re-lated macular degeneration. Can J Ophthalmol. 2000;35:27-32.
17. Redelmeier DA, Detsky AS. A clinician's guide to utility measurement. In: Bergus GR, Cantor SB, eds. Primary Care? Clinics in Office Practice. Philadelphia: WB Saunders; 1995;22: 271-280.
18. Drummond ME, O'Brien B, Stoddart GL, et al. Methodsfor the Economic Evaluation of Health Care Programmes. 2nd ed. New York: Oxford Univer-sity Press; 1999.
19. Brown GC Vision and quality of life. Trans Am Ophthalmol Soc 1999;97:473-512.
20. Brown MM, Brown GC, Sharma S, et al. Utility values associated with blindness in an adult population. Br J Ophthalmol. 2001;85:327-331.
21. Brown MM, Brown GC, Sharma S, et al. Qual-ity-of-life associated with unilateral and bilat-eral good vision. Ophthalmology. 2001;108: 643-647
22. Brown MM, Brown GC, Sharma S, et al. Quality of life associated with visual loss. Time tradeoff utility analysis comparison with systemic health states. Ophthalmology. 2003;110:1076-1081.
23. Brown MM, Brown GC, Sharma S, et al. Age-related macular degeneration. Its burden and a value-based medicine analysis. Can J Ophthalmol 2005;40:177-187
24. Brown MM, Brown GC, Sharma S, Landy J. Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Arch Ophthalmol. 2002;120:481-484.
25. Hollands H, Lam M, Pater J, et al. Reliability of the time trade-off technique of utility assess-ment in patients with retinal disease. Can J Ophthalmol. 2001;36:202-209.
26. Sonnenberg FA, Beck JR Markov models in medical decision making: A practical guide. Med Decis Making 1993;13:322-338.
27. Brown GC, Brown MM, Sharma S, et al. Cost-effectiveness of treatment for threshold retino-pathy of prematurity. Pediatrics. 1999;104:e47.
28. Brown GC, Brown MM, Sharma S. Incremental cost-effectiveness of laser therapy for subfoveal choroidal neovascularization. Ophthalmology. 2000;107:1374-1380.
29. Brown GC, Brown MM, Sharma S. Healthcarein the 21st century? Evidence-based medicine, pa-tient preference-based quality and cost-effective-ness. QualManage Health Care. 2000;19:23-31.
30. Damodaran A. Corporate Finance. Theory and Practice? Chapter 3. New York: John Wiley & Sons, Inc; 1997:37-65.